| Literature DB >> 28464794 |
Yun Tao Wu1,2, Lu Song2,3, Xiao Xue Liu4, Jing Sheng Gao2, Xiao Ming Zheng2, Chun Yu Ruan2, Hai Yan Zhao2, Shuo Hua Chen5, Wen Yuan Gao6, Jost B Jonas7, Shou Ling Wu8.
Abstract
BACKGROUND: With the marked increase in the prevalence of diabetes mellitus, it was the purpose of our study to assess a potential association of time-cumulated exposure to systolic (CumSBP) and of diastolic blood pressure (CumDBP) with onset of impaired glucose tolerance and diabetes mellitus.Entities:
Keywords: Cumulative blood pressure exposure; Incident diabetes; Incident glucose tolerance impairment; Kailuan study
Mesh:
Substances:
Year: 2017 PMID: 28464794 PMCID: PMC5414153 DOI: 10.1186/s12872-017-0537-y
Source DB: PubMed Journal: BMC Cardiovasc Disord ISSN: 1471-2261 Impact factor: 2.298
Fig. 1Scheme showing the inclusion and exclusion of study participants
Characteristics (Mean ± Standard deviation) of the study participants stratified by the cumulative systolic blood pressure
| Variables | Total population ( | Group 1 ( | Group 2 ( | Group 3 ( | Group 4 ( |
|
|---|---|---|---|---|---|---|
| Cumulative Systolic Blood Pressure (mmHg x year) | <480 | ≥480 and <520 | ≥520 and <560 | ≥560 | ||
| Men (n) | 29,129 (75.1%) | 10,461 (68.2%) | 5813 (80.6%) | 4528 (79.8%) | 8327 (78.7%) | <0.001 |
| Age (Years) | 47.82 ± 11.70 | 41.96 ± 9.75 | 46.54 ± 10.38 | 50.16 ± 10.64 | 55.94 ± 10.51 | <0.001 |
| Heart Rate (Beats/min) | 73.03 ± 9.69 | 72.46 ± 9.16 | 73.26 ± 9.64 | 73.26 ± 9.86 | 73.58 ± 10.32 | <0.001 |
| Systolic Blood Pressure (mmHg) | 126.9 ± 19.3 | 115.1 ± 12.7 | 125.4 ± 13.7 | 130.9 ± 15.9 | 143.1 ± 19.8 | <0.001 |
| Diastolic Blood Pressure (mmHg) | 82.1 ± 11.2 | 76.4 ± 8.8 | 82.1 ± 9.4 | 84.4 ± 10.3 | 88.9 ± 11.7 | <0.001 |
| Body Mass Index (kg/m2) | 24.89 ± 3.42 | 24.08 ± 3.31 | 25.06 ± 3.34 | 25.35 ± 3.39 | 25.71 ± 3.39 | <0.001 |
| Fasting Serum Concentration of Glucose (mmol/L) | 5.01 ± 0.65 | 4.96 ± 0.62 | 5.05 ± 0.65 | 5.04 ± 0.66 | 5.02 ± 0.68 | <0.001 |
| Total Cholesterol (mmol/L) | 4.89 ± 1.11 | 4.75 ± 1.05 | 4.87 ± 1.15 | 4.96 ± 1.14 | 5.07 ± 1.14 | <0.001 |
| High-Density Lipoproteins (mmol/L) | 1.55 ± 0.39 | 1.54 ± 0.37 | 1.54 ± 0.38 | 1.57 ± 0.42 | 1.57 ± 0.42 | <0.001 |
| Low-Density Lipoproteins (mmol/L) | 2.29 ± 0.89 | 2.26 ± 0.82 | 2.33 ± 0.86 | 2.30 ± 0.91 | 2.30 ± 1.01 | <0.001 |
| Uric Acid Concentration (μmol/L) | 284.7 ± 82.1 | 270.6 ± 77.3 | 284.0 ± 79.6 | 288.5 ± 81.3 | 303.3 ± 86.8 | <0.001 |
| Triglycerides (Median (Q1,Q3)) | 1.23 (0.86, 1.84) | 1.12 (0.78, 1.63) | 1.26 (0.89, 1.89) | 1.31 (0.93, 1.98) | 1.35 (0.96, 2.02) | <0.001 |
| High-Sensitive C-Reactive Protein (Median (Q1,Q3)) | 0.70 (0.27, 1.96) | 0.60 (0.20, 1.50) | 0.69 (0.25, 1.90) | 0.70 (0.30, 2.02) | 0.96 (0.38, 2.60) | <0.001 |
| Smoking (n) | 11,616 (29.9%) | 4423 (28.8%) | 2359 (32.7%) | 1772 (31.2%) | 3062 (29.0%) | <0.001 |
| Drinking (n) | 6608 (17.0%) | 1986 (12.9%) | 1323 (18.3%) | 1076 (19.0%) | 2223 (21.0%) | <0.001 |
| Exercise (n) | 5212 (13.4%) | 1244 (8.1%) | 779 (10.8%) | 831 (14.6%) | 2358 (22.3%) | <0.001 |
| Pressure-lowering drugs (n) | 3211 (8.3%) | 226 (1.5%) | 292 (4.0%) | 464 (8.2%) | 2229 (21.1%) | <0.001 |
| Education: Illiteracy / Primary (n) | 2655 (6.8%) | 473 (3.1%) | 404 (5.6%) | 426 (7.5%) | 1352 (12.8%) | <0.001 |
| Junior High School (n) | 26,706 (68.8%) | 10,294 (67.1%) | 5093 (70.6%) | 4083 (71.9%) | 7236 (68.4%) | |
| High School (n) | 6264 (16.1%) | 2864 (18.7%) | 1158 (16.1%) | 818 (14.4%) | 1424 (13.5%) | |
| College or Higher (n) | 3179 (8.2%) | 1708 (11.1%) | 559 (7.7%) | 348 (6.1%) | 564 (5.3%) |
Multiple COX regression model for the time-cumulated exposure to systolic blood pressure and to diastolic blood pressure in relation to the new-onset of impairment of glucose tolerance in 2563 (8.0%) individuals out of 31,935 participants without impairment of glucose tolerance and without diabetes at the baseline examinations
| New-onset of impairment of glucose tolerance in participants without impairment of glucose tolerance and without diabetes at the baseline | Quartiles of cumulative systolic blood pressure (cumSBP) | Each increase in cumSBP by 10 mmHg·/ year |
| |||
| Q1 | Q2 | Q3 | Q4 | |||
| cumSBP (Median) (mmHg x Year) | 439.1 | 498.6 | 538.4 | 614.1 | ||
| Number of Participants (n) | 775 (5.8%) | 439 (7.5%) | 399 (8.8%) | 950 (11.8%) | <0.001 | |
| Model 1 | 1.00 | 1.30 (1.15, 1.50) | 1.60 (1.41, 1.82) | 2.42 (2.17, 1.82) | 1.04 (1.03, 1.04) | <0.001 |
| Model 2 | 1.00 | 1.29 (1.14, 1.45) | 1.56 (1.37, 1.78) | 2.32 (2.07, 2.60) | 1.03 (1.03, 1.04) | <0.001 |
| Model 3 | 1.00 | 1.17 (1.02, 1.33) | 1.43 (1.25, 1.64) | 2.09 (1.85, 2.37) | 1.03 (1.03, 1.04) | <0.001 |
| New-onset of impairment of glucose tolerance in participants without impairment of glucose tolerance and without diabetes at the baseline | Quartiles of cumulative diastolic blood pressure (cumDBP) | Each increase in cumDBP by 5 mmHg·/ year |
| |||
| Q1 | Q2 | Q3 | Q4 | |||
| cumDBP (Median) (mmHg x Year) | 239.1 | 329.6 | 349.4 | 388.4 | ||
| Number of Participants (n) | 875 (6.1%) | 391 (7.6%) | 388 (9.0%) | 909 (11.1%) | <0.001 | |
| Model 1 | 1.00 | 1.26 (1.11, 1.42) | 1.55 (1.37, 1.75) | 2.35 (2.12, 2.60) | 1.03 (1.03, 1.03) | <0.001 |
| Model 2 | 1.00 | 1.24 (1.10, 1.40) | 1.53 (1.35, 1.73) | 2.27 (2.05, 2.52) | 1.03 (1.02, 1.03) | <0.001 |
| Model 3 | 1.00 | 1.12 (0.98, 1.27) | 1.35 (1.18, 1.54) | 2.02 (1.80, 2.25) | 1.02 (1.02, 1.03) | <0.001 |
CumSBP: Q 1:cumSBP < 480mmHgxyear,Q 2:480mmHgxyear ≤ cumSBP < 520mmHgxyear,Q 3:520mmHgxyear ≤ cumSBP < 560mmHgxyear,Q 4: cumSBP ≥ 560mmHgxyear
CumDBP: Q 1:cumDBP < 320mmHgxyear,Q 2:320mmHgxyear ≤ cumDBP < 340mmHgxyear,Q 3:340mmHgxyear ≤ cumDBP < 360mmHgxyear,Q 4: cumDBP ≥ 360mmHgxyear
Model 1: adjusted for sex and age (years)
Model 2: adjusted for model 1 and further adjusted for smoking, drinking, exercises, education and taking pressure-lowering drugs
Model 3: adjusted for model 2 and further adjusted for heart rate, body mass index, and fasting serum concentration of glucose, triglycerides, high-sensitive C-reactive protein, high-density lipoproteins, low-density lipoproteins and uric acid concentration
Multiple COX regression model for the time-cumulated exposure to systolic blood pressure and to diastolic blood pressure in relation to the new-onset of diabetes in 874 (12.7%) individuals out of 6869 participants with impaired glucose tolerance at the baseline examinations
| New-onset of diabetes in participants with impaired glucose tolerance at the baseline examinations | Quartiles of cumulative systolic blood pressure (cumSBP) | Each increase in cumSBP by 10 mmHg·/ year |
| |||
| Q1 | Q2 | Q3 | Q4 | |||
| cumSBP (Median) (mmHg x Year) | 446.9 | 498.9 | 539.2 | 620.4 | ||
| Number of Participants (n) | 181 (9.7%) | 148 (11.1%) | 155 (13.4%) | 390 (15.5%) | <0.001 | |
| Model 1 | 1.00 | 1.32 (1.06, 1.64) | 1.69 (1.35, 2.10) | 2.45 (2.00, 2.99) | 1.04 (1.03, 1.04) | <0.001 |
| Model 2 | 1.00 | 1.34 (1.08, 168) | 1.70 (1.36, 2.12) | 2.37 (1.93, 2.92) | 1.04 (1.03, 1.04) | <0.001 |
| Model 3 | 1.00 | 1.22 (0.97, 1.54) | 1.47 (1.16, 1.86) | 2.01 (1.62, 2.50) | 1.03 (1.03, 1.04) | <0.001 |
| New-onset of diabetes in participants with impaired glucose tolerance at the baseline examinations | ||||||
| Q1 | Q2 | Q3 | Q4 | Each increase in cumDBP by 5 mmHg·/ year |
| |
| cumDBP (Median) (mmHg x Year) | 299.2 | 329.5 | 349.5 | 391.8 | ||
| Number of Participants (n) | 228 (10.5%) | 123 (11.2%) | 139 (12.4%) | 384 (15.5%) | <0.001 | |
| Model 1 | 1.00 | 1.17 (0.93, 1.46) | 1.45 (1.17, 1.80) | 2.40 (2.01, 2.85) | 1.03 (1.03, 1.04) | <0.001 |
| Model 2 | 1.00 | 1.19 (00.95, 1.49) | 1.48 (1.19, 1.84) | 2.36 (1.97, 2.82) | 1.03 (1.03, 1.04) | <0.001 |
| Model 3 | 1.00 | 1.10 (0.87, 1.39) | 1.28 (1.02, 1.60) | 2.06 (1.70, 2.49) | 1.03 (1.02, 1.03) | <0.001 |
CumSBP: Q 1:cumSBP < 480mmHgxyear,Q 2:480mmHgxyear ≤ cumSBP < 520mmHgxyear,Q 3:520mmHgxyear ≤ cumSBP < 560mmHgxyear,Q 4: cumSBP ≥ 560mmHgxyear
CumDBP: Q 1:cumDBP < 320mmHgxyear,Q 2:320mmHgxyear ≤ cumDBP < 340mmHgxyear,Q 3:340mmHgxyear ≤ cumDBP < 360mmHgxyear,Q 4: cumDBP ≥ 360mmHgxyear
Model 1: adjusted for sex and age (years)
Model 2: adjusted for model 1 and further adjusted for smoking, drinking, exercises, education and taking pressure-lowering drugs
Model 3: adjusted for model 2 and further adjusted for heart rate, body mass index, and fasting serum concentration of glucose, triglycerides, high-sensitive C-reactive protein, high-density lipoproteins, low-density lipoproteins and uric acid concentration
Fig. 2a Development of Impairment of Glucose Tolerance in 2563 (8.0%) Individuals out of 31,935 Participants Without Impairment of Glucose Tolerance and Without Diabetes at the Baseline Examinations. b Development of New-Onset of Diabetes in 874 (12.7%) Individuals out of 6869 Participants with Impaired Glucose Tolerance at the Baseline Examinations